Page 1

JANUX Exhibit 99.1 Janux Therapeutics Reports Second Quarter 2021 Financial Results -Successful $ 222.9 million IPO in June brings total funds raised in the quarter to $ 347.9 million- -Company on - track to submit IND filings for multiple programs in 2022- -Management team strengthened with key appointments- SAN DIEGO , August 10 , 2021 – Janux Therapeutics , Inc. ( Nasdaq : JANX ) ( Janux ) , a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology , today reported financial results for the quarter ended June 30 , 2021 . " With the successful completions of a Series B financing and IPO this past quarter , we are well - capitalized to advance our novel TRACTr platform technology and next - generation T cell engager immunotherapies , with the potential to improve the treatment of cancer , " said David Campbell , Ph.D. , President and CEO of Janux . “ Janux has also significantly strengthened the organization with key hires to our senior management team . These team members bring invaluable expertise and decades of drug development experience , specifically in T cell therapeutics , to propel our broad preclinical pipeline toward the clinic . " Recent Business Highlights : • TRACTr product candidates advancing as planned . Janux's lead TRACTr programs of next - generation T cell engagers PSMA , EGFR , TROP2 , and its costimulatory bispecific TRACIr program remain on track as they move through preclinical development . Janux continues to expect to submit at least two Investigational New Drug ( IND ) applications by the end of 2022 . • for Strengthened management team with appointment of Shahram Salek - Ardakani , Ph.D. , as Chief Scientific Officer , and Wayne Godfrey , M.D. , as Chief Medical Officer . Dr. Salek - Ardakani brings more than 20 years of experience as a scientific leader and drug developer in multiple disease areas , most recently serving as the Senior Director of Cancer Immunology at Pfizer , Inc. , where he was responsible for formulating first - in - class discovery programs and platform initiatives to implement Pfizer's T cell targeted therapeutics strategy . Dr. Godfrey brings more than 25 years of drug development , clinical strategy , and research experience in cancer immunology and immunotherapy at leading pharmaceutical and biotechnology companies , most recently serving as the Vice President of Clinical Development at IGM Biosciences , Inc. , where he led the global clinical development of IGM's emerging pipeline of proprietary bispecific T cell engaging IgM antibodies . • Completed Series B financing and initial public offering ( IPO ) . In April 2021 , Janux completed a Series B financing , raising gross proceeds of $ 125.0 million . In June 2021 , Janux completed an initial public offering , selling 13,110,000 shares of its common stock at a price to the public of $ 17.00 per share , for aggregate gross proceeds of $ 222.9 million ( before deducting underwriting discounts and commissions and offering costs ) . Second Quarter 2021 Financial Highlights : • Cash and cash equivalents and short - term investments : As of June 30 , 2021 , Janux reported cash and cash equivalents and short- term investments of $ 394.2 million , compared to $ 7.8 million at December 31 , 2020 .